I’m excited to share this JournalFeed post on the AHA’s guidance for managing pediatric cardiogenic shock – a topic I thought would be especially valuable for the HipPEMcrates community.
As a JournalFeed contributor and user, I appreciate its concise, practical summaries that help busy clinicians keep up with the literature. The full post appears below, reproduced with permission from JournalFeed. Many thanks to Clay and the JournalFeed team for letting us share it!
If you enjoy this post, check out JournalFeed and consider subscribing for article summaries delivered to your inbox.
New AHA Policy – Managing Pediatric Cardiogenic Shock
Written by Sindhu Sudanagunta
Spoon Feed
This scientific statement by the American Heart Association provides a bedside framework for recognizing, staging, managing, and monitoring pediatric cardiogenic shock, while emphasizing timely phenotype-tailored therapy to reduce heart failure-related morbidity and mortality in children.
Pressure’s off: Why BP isn’t the whole story in pediatric cardiogenic shock
Cardiogenic shock (CS) causes life-threatening hypoperfusion and hypoxia with a high morbidity (mechanical ventilation, renal/liver failure) and mortality (25–50% based on population and cause) in children. Early recognition and disease-based intervention improve outcomes in this medically fragile population.
This study offers a clinically useful definition of CS as: “cardiac dysfunction (known or suspected) that results in clinical or biochemical evidence of tissue hypoperfusion or both, namely 1 or more of the following: cool extremities, elevated lactate (>2 mmol/L), abnormal liver or renal function testing, irritability, or altered mental status.” Notably, hypotension is NOT required, as it can be a late finding; hypoperfusion, not blood pressure, is the primary diagnostic anchor.
Early recognition requires high suspicion because CS often mimics viral or GI illness in children (ex: dyspnea, tachypnea, abdominal pain, nausea, decreased appetite). Specifically, left heart failure may reveal tachypnea, respiratory distress, hepatomegaly, or new gallop. Right heart failure or a failing Fontan circulation (stage 3 of single ventricle palliation) can present with systemic venous congestion such as ascites, pedal edema, and elevated jugular venous distention. Additional useful tests include chest radiograph, ECG, transthoracic echo (POCUS as a cursory surrogate), blood gas with lactate, liver enzymes, creatinine, albumin, INR (liver function), cystatin C, CBC, troponin, BNP, CRP, procalcitonin.
Management should be tailored to phenotype, with the goal to optimize oxygen delivery and improve tissue perfusion.
Vascular support:
- Epinephrine — relatively safe first choice; inotropic support; vasodilator at low dose (0.01–0.1 μg/kg/min), vasoconstrictor at high dose (>0.3 μg/kg/min); increases myocardial oxygen demand.
- Norepinephrine — vasoconstrictor; increases afterload, which decreases stroke volume and cardiac output; role in concurrent sepsis.
- Milrinone — inotrope and vasodilator; long half-life, poor for prehospital use.
- Fluids — use judiciously to optimize preload without exacerbating vascular congestion. Diuresis in the absence of hypotension reduces pulmonary edema and supports renal perfusion. Give fluids if concern for decreased preload, in small aliquots over a longer duration (5-7.5 ml/kg over 2-4hrs).
Respiratory support:
- Increases tissue oxygen delivery even in normoxemia.
- High-flow nasal cannula or BiPAP.
- Use oxygen cautiously in children with shunt physiology (Norwood, unrepaired VSD) — pulmonary vasodilation can worsen systemic cardiac output.
- Positive pressure ventilation reduces respiratory workload; avoid excessive pressure, which reduces preload and increases RV afterload.
- Induction during intubation can cause loss of SVR or myocardial depression. Ketamine is relatively safe; keep an epinephrine bolus available to assist in patients with catecholamine depletion, and have ECMO on standby, if available.
Children should be monitored closely, as the first 24 hours after diagnosis carry the highest risk for deterioration. Monitoring includes frequent vitals, physical exam, repeat labs, NIRS, venous CO-oximetry, and arterial pressures.
Decision for mechanical circulatory support is based on a synthesis of current support, oxygen requirement, response to therapy, hemodynamics, and disease phenotype. Engage the ECMO team early, as a planned initiation beats crashing on to ECMO.
This statement is almost entirely consensus-based, not RCT-derived, since pediatric CS trials are scarce. Several recommendations are derived from adult CS literature (largely MI-driven), which makes extrapolation to pediatrics difficult.
How will this change my practice?
The biggest impact for me is the explicit statement that blood pressure should not be the tripwire for diagnosing pediatric cardiogenic shock—by the time a child is hypotensive, they may already be well into heart failure, particularly in high-SVR states where the pressure can look reassuringly normal while cardiac output is failing. The signal to chase is hypoperfusion: cool extremities, decreased urine output, irritability, altered mentation, raising lactate, and end organ damage, with or without hypotension.
I am reassured that meds I’m comfortable with—epinephrine for inotropic support, ketamine for induction—hold up here too, as long as I watch the effect on cardiac function.
I also found it helpful to differentiate between biventricle and single-ventricle/shunt-dependent phenotypes. Below is how I organize my thoughts:
Dr. Joshua Belfer, MD, is a Pediatric Emergency Medicine physician at the Children’s Hospital of Philadelphia, and is the Founder and Editor-in-Chief of HipPEMcrates. He can be reached at HipPEMcrates@gmail.com.
